For example, epigenetic drugs, HDAC inhibitors, have demonstrated promising results in promoting immune editing of tumor neoantigens in vivo, as well as enhancing anti-tumor-specific immune responses [244]. The gene discussed is HDAC9; the disease is neoplasm.